Oncternal Therapeutics (ONCT) Competitors $0.53 0.00 (0.00%) As of 04/14/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCT vs. AYTU, ALZN, LIPO, RNAZ, GTBP, PRTG, FRTX, APLM, HOTH, and DWTXShould you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Aytu BioPharma (AYTU), Alzamend Neuro (ALZN), Lipella Pharmaceuticals (LIPO), TransCode Therapeutics (RNAZ), GT Biopharma (GTBP), Portage Biotech (PRTG), Fresh Tracks Therapeutics (FRTX), Apollomics (APLM), Hoth Therapeutics (HOTH), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry. Oncternal Therapeutics vs. Aytu BioPharma Alzamend Neuro Lipella Pharmaceuticals TransCode Therapeutics GT Biopharma Portage Biotech Fresh Tracks Therapeutics Apollomics Hoth Therapeutics Dogwood Therapeutics Oncternal Therapeutics (NASDAQ:ONCT) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership. Do analysts rate ONCT or AYTU? Oncternal Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 1,798.97%. Given Oncternal Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Oncternal Therapeutics is more favorable than Aytu BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncternal Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to ONCT or AYTU? In the previous week, Aytu BioPharma had 1 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 2 mentions for Aytu BioPharma and 1 mentions for Oncternal Therapeutics. Aytu BioPharma's average media sentiment score of 1.89 beat Oncternal Therapeutics' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncternal Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community favor ONCT or AYTU? Aytu BioPharma received 223 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 23.02% of users gave Oncternal Therapeutics an outperform vote. CompanyUnderperformOutperformOncternal TherapeuticsOutperform Votes3223.02% Underperform Votes10776.98% Aytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% Is ONCT or AYTU more profitable? Aytu BioPharma has a net margin of -7.62% compared to Oncternal Therapeutics' net margin of -1,599.95%. Aytu BioPharma's return on equity of -19.30% beat Oncternal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oncternal Therapeutics-1,599.95% -177.58% -131.30% Aytu BioPharma -7.62%-19.30%-4.80% Which has more risk and volatility, ONCT or AYTU? Oncternal Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500. Which has better valuation & earnings, ONCT or AYTU? Aytu BioPharma has higher revenue and earnings than Oncternal Therapeutics. Aytu BioPharma is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncternal Therapeutics$790K1.97-$39.48M-$11.69-0.05Aytu BioPharma$77.23M0.08-$15.84M-$1.45-0.71 Do institutionals and insiders hold more shares of ONCT or AYTU? 16.0% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by insiders. Comparatively, 2.8% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryAytu BioPharma beats Oncternal Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCT vs. The Competition Export to ExcelMetricOncternal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.56M$6.31B$5.32B$7.56BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-0.056.7821.7717.81Price / Sales1.97222.80378.2693.59Price / CashN/A65.6738.1534.64Price / Book0.055.826.443.99Net Income-$39.48M$141.86M$3.20B$247.23M7 Day PerformanceN/A8.99%6.42%7.24%1 Month PerformanceN/A-12.57%-8.66%-6.26%1 Year Performance-94.02%-12.38%10.27%-0.18% Oncternal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCTOncternal Therapeutics1.2513 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530AYTUAytu BioPharma1.4827 of 5 stars$1.00-2.9%N/A-61.0%$6.17M$77.23M-0.69160News CoverageGap DownALZNAlzamend Neuro2.5146 of 5 stars$0.93-5.5%$20.00+2,053.1%-89.7%$6.14MN/A0.004Short Interest ↑Gap DownLIPOLipella Pharmaceuticals2 of 5 stars$2.32-1.7%$16.00+589.7%-57.6%$5.91M$536,357.00-0.554Short Interest ↓Gap DownRNAZTransCode Therapeutics2.2159 of 5 stars$0.45-2.9%$20.00+4,394.4%-99.9%$5.83MN/A0.009Short Interest ↑GTBPGT Biopharma3.5047 of 5 stars$2.26-3.8%$11.00+386.7%-37.0%$5.73MN/A-0.328Short Interest ↓Gap DownPRTGPortage Biotech0.4669 of 5 stars$5.33-3.6%N/A+17.5%$5.59MN/A-0.136Short Interest ↑Gap DownFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+6.2%$5.59M$10.06M-0.6620APLMApollomics2.3862 of 5 stars$5.09-15.2%$200.00+3,829.3%-90.1%$5.53M$1.22M0.0045Gap DownHOTHHoth Therapeutics2.9855 of 5 stars$0.79-6.0%$4.00+406.4%-32.2%$5.45MN/A-0.604Analyst ForecastDWTXDogwood TherapeuticsN/A$4.05-4.7%N/AN/A$5.40MN/A-0.625 Remove Ads Related Companies and Tools Related Companies AYTU Alternatives ALZN Alternatives LIPO Alternatives RNAZ Alternatives GTBP Alternatives PRTG Alternatives FRTX Alternatives APLM Alternatives HOTH Alternatives DWTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONCT Stock Free ONCT Stock Alerts